Literature DB >> 20979758

[Protective effect of Xingnaojing and Xuesaitong injections on cerebral ischemic reperfusion injury in rats].

Feng Guo1, Xiao-Wei Lu, Qiu-Ping Xu.   

Abstract

OBJECTIVE: To investigate the mechanism of protective effect of Xingnaojing and Xuesaitong injections on cerebral ischemic reperfusion injury in rats.
METHODS: The focal cerebral ischemia & reperfusion model was established by middle cerebral artery occlusion (MCAO). A total of 152 male SD rats were randomly assigned into 19 groups: sham operated group, Xingnaojing group, Xingnaojing plus Xuesaitong group and control group according to different reperfusion durations: 2, 4, 8, 24, 48, 72 h. Each group had 8 rats. Rats in Xingnaojing group received the ip injections of Xingnaojing (1 ml x 100 (-1) x d(-1)) until an onset of ischemia; Xingnaojing plus Xuesaitong group received the ip injections of Xingnaojing (1 ml x 100 g(-1) x d(-1)) and Xuesaitong (1 ml x 100 g(-1) x d(-1)) until an onset of ischemia; In the meantime, rats in control group received the same ip dose of saline. The levels of SOD and MDA were detected. The number of apoptotic neurons was detected by terminal-deoxynucleotidyl transferase medicated nick end labeling (TUNEL).
RESULTS: During ischemic reperfusion, the MDA content of brain homogenate increased while the SOD activity decreased (P < 0.05). Xingnaojing could significantly inhibit the increase of MDA after cerebral ischemic reperfusion (P < 0.05) and the decrease of SOD activity in rats. The changes of SOD and MDA were smaller in the Xingnaojing plus Xuesaitong group than those in the Xinnaojing group (P < 0.01). The number of apoptotic neurons in the Xingnaojing group was significantly lower than that in control group (P < 0.05). And the number of apoptotic neurons in the Xingnaojing plus Xuesaitong group was even lower than that in the Xingnaojing group(4,8 h: P < 0.05, 24, 48, 72 h: P < 0.01).
CONCLUSION: The Xingnaojing plus Xuesaitong injection has protective function after cerebral ischemic reperfusion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20979758

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  6 in total

1.  Comparative pharmacokinetics of borneol in cerebral ischemia-reperfusion and sham-operated rats.

Authors:  Pan Xu; Ying Li; Shou-ying Du; Yang Lu; Jie Bai; Qing-li Guo
Journal:  J Zhejiang Univ Sci B       Date:  2014-01       Impact factor: 3.066

2.  Pre-treatment with a Xingnaojing preparation ameliorates sevoflurane-induced neuroapoptosis in the infant rat striatum.

Authors:  Zhou-Jing Yang; Ying-Wei Wang; Chang-Lin Li; Li-Qing Ma; Xuan Zhao
Journal:  Mol Med Rep       Date:  2014-11-13       Impact factor: 2.952

Review 3.  Role of Xingnaojing combined with naloxone in treating intracerebral haemorrhage: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Yu-Min Xu; Xin-Chen Wang; Shi-Jie Zhang; Ting-Ting Xu; Hong-Ying Li; Shang-Yan Hei; Ze-Huai Wen; Yun-Zhi Ma; Qi Wang; Wei-Xiong Liang
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

Review 4.  Preclinical Evidence and Mechanism of Xingnaojing Injection for Cerebral Ischemia: A Systematic Review and Meta-Analysis of Animal Studies.

Authors:  Rong Ma; Xiao Ma; Jianxia Wen; Jian Wang; Qian Xie; Nian Chen; Taiwei Dong
Journal:  Evid Based Complement Alternat Med       Date:  2018-11-15       Impact factor: 2.629

Review 5.  Systematic review and meta-analysis of randomized controlled trials of xingnaojing treatment for stroke.

Authors:  Weijun Peng; Jingjing Yang; Yang Wang; Weihao Wang; Jianxia Xu; Lexing Wang; Zhihua Xing
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-24       Impact factor: 2.629

Review 6.  Ameliorating effects of traditional Chinese medicine preparation, Chinese materia medica and active compounds on ischemia/reperfusion-induced cerebral microcirculatory disturbances and neuron damage.

Authors:  Kai Sun; Jingyu Fan; Jingyan Han
Journal:  Acta Pharm Sin B       Date:  2015-01-24       Impact factor: 11.413

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.